Rubedo gains FDA clearance for senotherapeutic trial

Company advances candidate targeting senescent cells into US study with potential applications beyond dermatology. Rubedo Life Sciences has announced that the US Food and Drug Administration has cleared its Investigational New Drug application for RLS-1496, a selective modulator of glutathione peroxidase 4 (GPX4). The company will now move into a Phase 1b/2a trial in patients […] The post Rubedo gains FDA clearance for senotherapeutic trial appeared first on Longevity.Technology.